193 related articles for article (PubMed ID: 36882702)
1. Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors.
Hayashi K; Suzuki O; Shiomi H; Ono H; Setoguchi A; Nakai M; Nakanishi E; Tatekawa S; Ose N; Hirata T; Tamari K; Seo Y; Funaki S; Isohashi F; Shimizu S; Shintani Y; Ogawa K
BMC Cancer; 2023 Mar; 23(1):215. PubMed ID: 36882702
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Ablative Radiotherapy Using CyberKnife for Stage I Non-small-cell Lung Cancer: A Retrospective Analysis.
Hayashi K; Suzuki O; Shiomi H; Nakai M; Fujiwara K; Nakanishi E; Tatekawa S; Hirata T; Tamari K; Hirata H; Funaki S; Seo Y; Takeda Y; Isohashi F; Shintani Y; Ogawa K
Anticancer Res; 2022 Jan; 42(1):321-327. PubMed ID: 34969740
[TBL] [Abstract][Full Text] [Related]
3. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
5. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
6. CyberKnife for hilar lung tumors: report of clinical response and toxicity.
Unger K; Ju A; Oermann E; Suy S; Yu X; Vahdat S; Subramaniam D; Harter KW; Collins SP; Dritschilo A; Anderson E; Collins BT
J Hematol Oncol; 2010 Oct; 3():39. PubMed ID: 20969774
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
8. A 54 Gy in three fractions of stereotactic body radiotherapy using CyberKnife for T1b-2aN0M0 pathologically confirmed non-small cell lung cancer.
Abe T; Ryuno Y; Iino M; Saito S; Aoshika T; Ohta T; Igari M; Hirai R; Kumazaki Y; Kaira K; Kagamu H; Ishida H; Noda SE; Kato S
Jpn J Clin Oncol; 2021 Dec; 51(12):1723-1728. PubMed ID: 34580722
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors.
Iwata H; Ishikura S; Murai T; Iwabuchi M; Inoue M; Tatewaki K; Ohta S; Yokota N; Shibamoto Y
Int J Clin Oncol; 2017 Aug; 22(4):706-714. PubMed ID: 28429140
[TBL] [Abstract][Full Text] [Related]
11. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
13. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.
Takeda A; Oku Y; Sanuki N; Eriguchi T; Aoki Y; Enomoto T; Kaneko T; Nishimura S; Kunieda E
J Radiat Res; 2014 Sep; 55(5):988-95. PubMed ID: 24833770
[TBL] [Abstract][Full Text] [Related]
15. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
[TBL] [Abstract][Full Text] [Related]
16. Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
Sood S; Ganju R; Shen X; Napel MT; Wang F
Clin Lung Cancer; 2021 May; 22(3):e301-e312. PubMed ID: 33132058
[TBL] [Abstract][Full Text] [Related]
17. Pilot Study of the Safety and Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumors.
Mitsuyoshi T; Matsuo Y; Shintani T; Iizuka Y; Ueki N; Nakamura M; Mizowaki T
Clin Lung Cancer; 2018 May; 19(3):e287-e296. PubMed ID: 29277565
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for adenoid cystic carcinoma metastatic to the lung: a case report.
Kobayashi D; Abe T; Saitoh JI; Oike T; Sato H; Musha A; Mizukami T; Shimizu T; Nakano T; Ohno T
J Med Case Rep; 2021 Apr; 15(1):156. PubMed ID: 33838695
[TBL] [Abstract][Full Text] [Related]
19. Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy.
Loi M; Franceschini D; Dominici L; Chiola I; Franzese C; D'Agostino GR; Navarria P; Marzo M; Paganini L; Comito T; Mancosu P; Tomatis S; Cozzi L; Alifano M; Scorsetti M
Strahlenther Onkol; 2021 May; 197(5):396-404. PubMed ID: 32970163
[TBL] [Abstract][Full Text] [Related]
20. Clinical Results of Mean GTV Dose Optimized Robotic-Guided Stereotactic Body Radiation Therapy for Lung Tumors.
Baumann R; Chan MKH; Pyschny F; Stera S; Malzkuhn B; Wurster S; Huttenlocher S; Szücs M; Imhoff D; Keller C; Balermpas P; Rades D; Rödel C; Dunst J; Hildebrandt G; Blanck O
Front Oncol; 2018; 8():171. PubMed ID: 29868486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
